Back to search

Article

BRCA testing and Japanese original testing criteria for hereditary breast and ovarian cancer covered by public health insurance

2023-05-08

Abstract excerpt

<title>Abstract</title> <p>In Japan, <italic>BRCA1/2</italic> testing has been made available to the public as a companion diagnostic test for olaparib since July 2018. This testing indication has been expanded to diagnosis of hereditary breast and ovarian cancer. The Japanese breast cancer society (JBCS) issued original guidance and criteria to estimate eligibility for <italic>BRCA</italic> testing among breast...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
1895b034-34f3-5ce7-a9df-af59a3d68700
DOI
10.21203/rs.3.rs-2901558/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
BRCA testing and Japanese original testing criteria for hereditary breast and ovarian cancer covered by public health insuranceDOI 10.21203/rs.3.rs-2901558/v1
Efficacy of clinical guidelines in identifying all Japanese patients with hereditary breast and ovarian cancerSemantic proximity
Genetic and clinical characteristics in Japanese hereditary breast and ovarian cancer: first report after establishment of HBOC registration system in Japan.Semantic proximity
Development of a novel prediction model for carriage of BRCA1/2 pathogenic variant in Japanese patients with breast cancer based on Japanese Organization of Hereditary Breast and Ovarian Cancer registry dataSemantic proximity
The frequency and pathogenicity of BRCA1 and BRCA2 variants in the general Japanese population.Semantic proximity
Efficacy of Clinical Guidelines in Identifying All Japanese Patients with Hereditary Breast and Ovarian Cancer.Semantic proximity
Utility of Expedited Hereditary Cancer Testing in the Surgical Management of Patients with a New Breast Cancer Diagnosis.Semantic proximity
Hereditary breast and ovarian cancer (HBOC): review of its molecular characteristics, screening, treatment, and prognosis.Semantic proximity
Long-term oncologic outcomes of unselected triple-negative breast cancer patients according to BRCA1/2 mutationsSemantic proximity
Which Patients Do We Need to Test for BRCA1/2 Mutation? Feasibility of Adjuvant Olaparib Treatment in Early Breast Cancer–Real-World Data from Two Large German Breast CentersSemantic proximity
Prevalence of hereditary breast and ovarian cancer (HBOC) predisposition gene mutations among 882 HBOC high-risk Chinese individuals.Semantic proximity
BRCA1 and BRCA2 germline mutation analysis from a cohort of 1,267 high-risk breast cancer patients in BrazilSemantic proximity
Reinterpretation of BRCA1 and BRCA2 variants of uncertain significance in patients with hereditary breast/ovarian cancer using the ACMG/AMP 2015 guidelinesSemantic proximity
Select a neighboring publication to make it the new centre.